Glucotrack, Inc. (NASDAQ: GCTK) targets LT-100 single-injection study in 2026
Rhea-AI Filing Summary
Glucotrack, Inc., through its wholly owned subsidiary Lōkahi Therapeutics, reported progress on the development strategy for LT-100, aiming to simplify dosing from a historical regimen of up to 15 intradermal injections per treatment visit to a single subcutaneous injection per visit.
In a Type C meeting with the U.S. Food and Drug Administration in May 2026, the company discussed its proposed clinical strategy. A subsequent nonclinical minipig study comparing systemic exposure for subcutaneous versus intradermal administration provided information supporting planned clinical evaluation of the single-injection approach. Subject to ongoing development activities and regulatory review, clinical evaluation of single-injection LT-100 is anticipated as early as the fourth quarter of 2026, with a potential initial readout during the first half of 2027.
Positive
- None.
Negative
- None.
Insights
Analyzing...
8-K Event Classification
Key Figures
Key Terms
Type C meeting regulatory
intradermal medical
subcutaneous medical
systemic exposure medical
Investigational Device medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Glucotrack (GCTK) announce about LT-100 in this 8-K?
How is Lōkahi Therapeutics changing LT-100 administration for Glucotrack (GCTK)?
What is the planned clinical timeline for LT-100 under Glucotrack (GCTK)?
What was discussed in the FDA Type C meeting regarding Glucotrack (GCTK) asset LT-100?
What is Lōkahi Therapeutics’ role within Glucotrack (GCTK)?
What other technologies is Glucotrack (GCTK) developing besides LT-100?
What key risks does Glucotrack (GCTK) highlight in connection with LT-100 and its business?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or Other Jurisdiction | (Commission | (IRS Employer | ||
| of Incorporation) | File Number) | Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s
telephone number, including area code:
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure
On July 29, 2026, Glucotrack, Inc., a Delaware corporation (the “Company”), issued a joint press release with Lokahi Therapeutics Inc (the “Press Release”). The Press Release is furnished herewith as Exhibit 99.1.
The information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, unless the Company specifically states that the information is to be considered “filed” under the Exchange Act or specifically incorporates it by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
| Exhibit No. | Description | |
| 99.1 | Press Release dated July 29, 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: July 30, 2026 | ||
| GLUCOTRACK, INC. | ||
| By: | /s/ Erik Emerson | |
| Name: | Erik Emerson | |
| Title: | Chief Executive Officer | |
Exhibit 99.1
 |
 |
Lōkahi Therapeutics™ Advances LT-100 Development Strategy Toward Single-Injection Administration
FDA Type C Meeting and Nonclinical Study Advance Strategy to Transition LT-100 from 15 Injections to One
RUTHERFORD, N.J., and LA JOLLA, CA, July 29, 2026 – Lōkahi Therapeutics™ Inc., a wholly owned subsidiary of Glucotrack, Inc. (NASDAQ: GCTK), today announced progress in its LT-100 development strategy focused on evaluating whether a historical administration approach requiring up to 15 intradermal (ID) injections per treatment visit can be simplified to a single subcutaneous (SC) injection per visit. During a Type C meeting with the U.S. Food and Drug Administration in May 2026, the Company discussed its proposed clinical strategy for LT-100. Following that meeting, Lōkahi completed a nonclinical minipig study designed to compare systemic exposure following subcutaneous and intradermal administration of LT-100. The results provided important information to support the Company’s planned clinical evaluation of a single-injection administration approach.
Building on the Type C meeting and the results of the nonclinical study, Lōkahi is preparing for the next phase of LT-100 development, which is expected to include clinical evaluation of LT-100 administered as a single subcutaneous injection. Subject to completion of ongoing development activities and regulatory review, the Company currently anticipates initiating clinical evaluation of this administration approach as early as the fourth quarter of 2026, with an initial readout potentially occurring during the first half of 2027.
Historically, in clinical trials, LT-100 has been administered through up to 15 intradermal injections per treatment visit. Lōkahi’s current development objective is to determine whether that administration approach can be simplified to a single subcutaneous injection while maintaining a development strategy informed by prior clinical experience.
“The difference between 15 injections and one injection speaks for itself,” said Erik Emerson, Chief Executive Officer of Lōkahi Therapeutics™. “The Type C meeting helped define a path forward. We then completed the work necessary to evaluate that path, and the results give us confidence to move toward clinical evaluation of this simplified administration strategy. Our focus now is preparing to test this approach in the clinic.”
“Our objective was straightforward,” said Susan Kramer, Senior Vice President of Development at Lōkahi Therapeutics™. “We wanted to understand whether subcutaneous administration could achieve systemic exposure consistent with prior clinical experience using intradermal administration. The study provided this and other important information to guide the next stage of LT-100 clinical development.”
About Lōkahi Therapeutics™
Lōkahi Therapeutics is a capital-efficient biopharmaceutical platform company focused on identifying, evaluating, acquiring, and advancing overlooked therapeutic assets. Through its ai² platform and ai² Futures Lab execution model, Lōkahi integrates cross-functional expertise and disciplined decision-making to drive strategic development and long-term value creation. For more information, visit www.lokahithera.com.
About Glucotrack, Inc.
Glucotrack, Inc. (NASDAQ: GCTK) operates Lōkahi and, through its subsidiary Glucotrack Technologies, Inc., is also focused on the design, development, and commercialization of novel technologies for people with diabetes, including a long-term implantable continuous blood glucose monitoring system. The Glucotrack CBGM is an Investigational Device and is limited by federal (or United States) law to investigational use. For more information, please visit www.glucotrack.com.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “anticipate”, “believe”, “expect”, “plan,” and “will” are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and Glucotrack undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by Glucotrack will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Readers are cautioned that certain important factors may affect Glucotrack’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Glucotrack’s results include, but are not limited to, the ability of Glucotrack to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to merger integration; risks relating to the receipt (and timing) of regulatory approvals (including U.S. Food and Drug Administration approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to Glucotrack’s future distribution agreements; risks relating to its ability to hire and retain qualified personnel; and the additional risk factors described in Glucotrack’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2025 as filed with the SEC on March 30, 2026.
Contact:
Glucotrack
GlucotrackPR@icrinc.com
Lōkahi Therapeutics™
ir@lokahithera.com